Advertisement

Gastrointestinal Stromal Tumor

New Insights for a Multimodal Approach
  • Ashwyn K. Sharma
    Affiliations
    Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, CA, USA

    Moores Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Box 0987, La Jolla, CA 92093, USA
    Search for articles by this author
  • Teresa S. Kim
    Affiliations
    Department of Surgery, University of Washington, 1959 NE Pacific Street, Box 356410, Seattle, WA 98195, USA
    Search for articles by this author
  • Sebastian Bauer
    Affiliations
    Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Hospital Essen Hufelandstr. 55, Essen 45122, Germany

    DKTK Partner Site Essen, German Cancer Consortium (DKTK), Heidelberg, Germany
    Search for articles by this author
  • Jason K. Sicklick
    Correspondence
    Corresponding author. Moores Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Box 0987, La Jolla, CA 92093.
    Affiliations
    Department of Surgery, Division of Surgical Oncology, University of California San Diego, San Diego, CA, USA

    Moores Cancer Center, University of California San Diego School of Medicine, 3855 Health Sciences Drive, Box 0987, La Jolla, CA 92093, USA
    Search for articles by this author

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ma G.L.
        • Murphy J.D.
        • Martinez M.E.
        • et al.
        Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study.
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 298-302
        • Coe T.M.
        • Sicklick J.K.
        Epidemiology of GIST.
        in: Scoggins C.R. Raut C.P. Mullen J.T. Gastrointestinal stromal tumors: bench to bedside. Springer International Publishing, Cham2017: 7-15
        • Roland C.L.
        • Feig B.W.
        History of GIST.
        in: Scoggins C.R. Raut C.P. Mullen J.T. Gastrointestinal stromal tumors: bench to bedside. Springer International Publishing, Cham2017: 1-5
        • Hirota S.
        • Isozaki K.
        • Moriyama Y.
        • et al.
        Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
        Science. 1998; 279: 577-580
        • Heinrich M.C.
        • Corless C.L.
        • Duensing A.
        • et al.
        PDGFRA activating mutations in gastrointestinal stromal tumors.
        Science. 2003; 299: 708-710
        • Miettinen M.
        • Fetsch J.F.
        • Sobin L.H.
        • et al.
        Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases.
        Am J Surg Pathol. 2006; 30: 90-96
        • McWhinney S.R.
        • Pasini B.
        • Stratakis C.A.
        • et al.
        Familial gastrointestinal stromal tumors and germ-line mutations.
        N Engl J Med. 2007; 357: 1054-1056
        • Agaram N.P.
        • Wong G.C.
        • Guo T.
        • et al.
        Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
        Genes Chromosomes Cancer. 2008; 47: 853-859
        • Killian J.K.
        • Miettinen M.
        • Walker R.L.
        • et al.
        Recurrent epimutation of SDHC in gastrointestinal stromal tumors.
        Sci Transl Med. 2014; 6: 268ra177
        • Brenca M.
        • Rossi S.
        • Polano M.
        • et al.
        Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.
        J Pathol. 2016; 238: 543-549
        • Shi E.
        • Chmielecki J.
        • Tang C.M.
        • et al.
        FGFR1 and NTRK3 actionable alterations in "wild-type" gastrointestinal stromal tumors.
        J Transl Med. 2016; 14: 339
        • Haller F.
        • Moskalev E.A.
        • Faucz F.R.
        • et al.
        Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad.
        Endocr Relat Cancer. 2014; 21: 567-577
        • Yohe S.
        • Thyagarajan B.
        Review of clinical next-generation sequencing.
        Arch Pathol Lab Med. 2017; 141: 1544-1557
        • Gastrointestinal Stromal Tumor Meta-Analysis G.
        Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.
        J Clin Oncol. 2010; 28: 1247-1253
        • Casali P.G.
        • Blay J.Y.
        • Abecassis N.
        • et al.
        Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2022; 33: 20-33
        • Network N.C.C.
        Gastrointestinal stromal tumors (version 1.2022).
        (Available at:)
        • Florindez J.
        • Trent J.
        Low frequency of mutation testing in the United States: an analysis of 3866 GIST patients.
        Am J Clin Oncol. 2020; 43: 270-278
        • Verschoor A.J.
        • Bovee J.
        • Overbeek L.I.H.
        • et al.
        The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study.
        Virchows Arch. 2018; 472: 221-229
        • Banerjee S.
        • Kumar A.
        • Lopez N.
        • et al.
        Cost-effectiveness analysis of genetic testing and tailored first-line therapy for patients with metastatic gastrointestinal stromal tumors.
        JAMA Netw Open. 2020; 3e2013565
        • Fernandez J.A.
        • Gomez-Ruiz A.J.
        • Olivares V.
        • et al.
        Clinical and pathological features of "small" GIST (</=2 cm). What is their prognostic value?.
        Eur J Surg Oncol. 2018; 44: 580-586
        • Nishida T.
        • Goto O.
        • Raut C.P.
        • et al.
        Diagnostic and treatment strategy for small gastrointestinal stromal tumors.
        Cancer. 2016; 122: 3110-3118
        • Rossi S.
        • Gasparotto D.
        • Toffolatti L.
        • et al.
        Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.
        Am J Surg Pathol. 2010; 34: 1480-1491
        • Agaimy A.
        • Wunsch P.H.
        • Hofstaedter F.
        • et al.
        Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations.
        Am J Surg Pathol. 2007; 31: 113-120
        • Coe T.M.
        • Fero K.E.
        • Fanta P.T.
        • et al.
        Population-based epidemiology and mortality of small malignant gastrointestinal stromal tumors in the USA.
        J Gastrointest Surg. 2016; 20: 1132-1140
        • Agaimy A.
        • Wunsch P.H.
        • Dirnhofer S.
        • et al.
        Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: a clinicopathologic, immunohistochemical, and molecular study of 19 lesions.
        Am J Surg Pathol. 2008; 32: 867-873
        • Fero K.E.
        • Coe T.M.
        • Fanta P.T.
        • et al.
        Surgical management of adolescents and young adults with gastrointestinal stromal tumors: a US population-based analysis.
        JAMA Surg. 2017; 152: 443-451
        • NS I.J.
        • Drabbe C.
        • den Hollander D.
        • et al.
        Gastrointestinal stromal tumours (GIST) in young adult (18-40 years) patients: a report from the Dutch GIST Registry.
        Cancers (Basel). 2020; 12https://doi.org/10.3390/cancers12030730
        • Weldon C.B.
        • Madenci A.L.
        • Boikos S.A.
        • et al.
        Surgical management of wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Pediatric and Wildtype GIST Clinic.
        J Clin Oncol. 2017; 35: 523-528
        • Joensuu H.
        Risk stratification of patients diagnosed with gastrointestinal stromal tumor.
        Hum Pathol. 2008; 39: 1411-1419
        • Dematteo R.P.
        • Ballman K.V.
        • Antonescu C.R.
        • et al.
        Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
        Lancet. 2009; 373: 1097-1104
        • Joensuu H.
        • Eriksson M.
        • Sundby Hall K.
        • et al.
        One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
        JAMA. 2012; 307: 1265-1272
        • Joensuu H.
        • Eriksson M.
        • Sundby Hall K.
        • et al.
        Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up.
        JAMA Oncol. 2020; 6: 1241-1246
        • Raut C.P.
        • Espat N.J.
        • Maki R.G.
        • et al.
        Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 Clinical Trial.
        JAMA Oncol. 2018; 4e184060
        • Rutkowski P.
        • Gronchi A.
        • Hohenberger P.
        • et al.
        Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
        Ann Surg Oncol. 2013; 20: 2937-2943
        • Cavnar M.J.
        • Seier K.
        • Gonen M.
        • et al.
        Prognostic factors after neoadjuvant imatinib for newly diagnosed primary gastrointestinal stromal tumor.
        J Gastrointest Surg. 2021; 25: 1828-1836
        • Shu P.
        • Sun X.F.
        • Fang Y.
        • et al.
        Clinical outcomes of different therapeutic modalities for rectal gastrointestinal stromal tumor: summary of 14-year clinical experience in a single center.
        Int J Surg. 2020; 77: 1-7
        • Farid M.
        • Lee M.J.
        • Chew M.H.
        • et al.
        Localized gastrointestinal stromal tumor of the rectum: an uncommon primary site with prominent disease and treatment-related morbidities.
        Mol Clin Oncol. 2013; 1: 190-194
        • Jakob J.
        • Mussi C.
        • Ronellenfitsch U.
        • et al.
        Gastrointestinal stromal tumor of the rectum: results of surgical and multimodality therapy in the era of imatinib.
        Ann Surg Oncol. 2013; 20: 586-592
        • Cavnar M.J.
        • Wang L.
        • Balachandran V.P.
        • et al.
        Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: organ preservation and improved oncologic outcome.
        Ann Surg Oncol. 2017; 24: 3972-3980
        • Stuart E.
        • Banerjee S.
        • de la Torre J.
        • et al.
        Frequent rectal gastrointestinal stromal tumor recurrences in the imatinib era: retrospective analysis of an International Patient Registry.
        J Surg Oncol. 2019; 120: 715-721
        • Demetri G.D.
        • von Mehren M.
        • Blanke C.D.
        • et al.
        Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
        N Engl J Med. 2002; 347: 472-480
        • Heinrich M.C.
        • Rankin C.
        • Blanke C.D.
        • et al.
        Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG Intergroup Trial S0033.
        JAMA Oncol. 2017; 3: 944-952
        • Patrikidou A.
        • Chabaud S.
        • Ray-Coquard I.
        • et al.
        Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial.
        Ann Oncol. 2013; 24: 1087-1093
        • Le Cesne A.
        • Ray-Coquard I.
        • Bui B.N.
        • et al.
        Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.
        Lancet Oncol. 2010; 11: 942-949
        • Papaetis G.S.
        • Syrigos K.N.
        Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.
        BioDrugs. 2009; 23: 377-389
        • Demetri G.D.
        • van Oosterom A.T.
        • Garrett C.R.
        • et al.
        Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
        Lancet. 2006; 368: 1329-1338
        • Heinrich M.C.
        • Maki R.G.
        • Corless C.L.
        • et al.
        Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
        J Clin Oncol. 2008; 26: 5352-5359
        • Wilhelm S.M.
        • Dumas J.
        • Adnane L.
        • et al.
        Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
        Int J Cancer. 2011; 129: 245-255
        • Demetri G.D.
        • Reichardt P.
        • Kang Y.K.
        • et al.
        Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
        Lancet. 2013; 381: 295-302
        • Janku F.
        • Abdul Razak A.R.
        • Chi P.
        • et al.
        Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib.
        J Clin Oncol. 2020; 38: 3294-3303
        • Blay J.Y.
        • Serrano C.
        • Heinrich M.C.
        • et al.
        Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2020; 21: 923-934
        • Heinrich M.C.
        • Jones R.L.
        • von Mehren M.
        • et al.
        Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
        Lancet Oncol. 2020; 21: 935-946
        • Kang Y.K.
        • George S.
        • Jones R.L.
        • et al.
        Avapritinib versus regorafenib in locally advanced unresectable or metastatic gi stromal tumor: a randomized, open-label phase III study.
        J Clin Oncol. 2021; 39: 3128-3139
        • Drilon A.
        • Laetsch T.W.
        • Kummar S.
        • et al.
        Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.
        N Engl J Med. 2018; 378: 731-739
        • Doebele R.C.
        • Drilon A.
        • Paz-Ares L.
        • et al.
        Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
        Lancet Oncol. 2020; 21: 271-282
        • Pantaleo M.A.
        • Tarantino G.
        • Agostinelli C.
        • et al.
        Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.
        Oncoimmunology. 2019; 8e1617588
        • Cavnar M.J.
        • Zeng S.
        • Kim T.S.
        • et al.
        KIT oncogene inhibition drives intratumoral macrophage M2 polarization.
        J Exp Med. 2013; 210: 2873-2886
        • Rusakiewicz S.
        • Semeraro M.
        • Sarabi M.
        • et al.
        Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors.
        Cancer Res. 2013; 73: 3499-3510
        • Vitiello G.A.
        • Bowler T.G.
        • Liu M.
        • et al.
        Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.
        J Clin Invest. 2019; 129: 1863-1877
        • Balachandran V.P.
        • Cavnar M.J.
        • Zeng S.
        • et al.
        Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.
        Nat Med. 2011; 17: 1094-1100
        • Borg C.
        • Terme M.
        • Taieb J.
        • et al.
        Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
        J Clin Invest. 2004; 114: 379-388
        • Liu M.
        • Etherington M.S.
        • Hanna A.
        • et al.
        Oncogenic KIT modulates type I IFN-mediated antitumor immunity in GIST.
        Cancer Immunol Res. 2021; 9: 542-553
        • D'Angelo S.P.
        • Shoushtari A.N.
        • Keohan M.L.
        • et al.
        Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of dasatinib plus ipilimumab.
        Clin Cancer Res. 2017; 23: 2972-2980
        • Reilley M.J.
        • Bailey A.
        • Subbiah V.
        • et al.
        Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.
        J Immunother Cancer. 2017; 5: 35
        • Wolchok J.D.
        • Chiarion-Sileni V.
        • Gonzalez R.
        • et al.
        Overall survival with combined nivolumab and ipilimumab in advanced melanoma.
        N Engl J Med. 2017; 377: 1345-1356
        • Singh A.S.
        • Hecht J.R.
        • Rosen L.
        • et al.
        A randomized phase II study of nivolumab monotherapy or nivolumab combined with ipilimumab in patients with advanced gastrointestinal stromal tumors.
        Clin Cancer Res. 2021; https://doi.org/10.1158/1078-0432.CCR-21-0878
        • Seifert A.M.
        • Zeng S.
        • Zhang J.Q.
        • et al.
        PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors.
        Clin Cancer Res. 2017; 23: 454-465
        • Zhang J.Q.
        • Zeng S.
        • Vitiello G.A.
        • et al.
        Macrophages and CD8(+) T cells mediate the antitumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors.
        Cancer Immunol Res. 2018; 6: 434-447
        • Fairweather M.
        • Balachandran V.P.
        • Li G.Z.
        • et al.
        Cytoreductive surgery for metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors: a 2-institutional analysis.
        Ann Surg. 2018; 268: 296-302
        • Bauer S.
        • Rutkowski P.
        • Hohenberger P.
        • et al.
        Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG Collaborative Study).
        Eur J Surg Oncol. 2014; 40: 412-419
        • Du C.Y.
        • Zhou Y.
        • Song C.
        • et al.
        Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
        Eur J Cancer. 2014; 50: 1772-1778